Sareum Holdings PLC Notice of Results and Investor Presentation (4432O)
October 03 2023 - 2:00AM
UK Regulatory
TIDMSAR
RNS Number : 4432O
Sareum Holdings PLC
03 October 2023
Sareum Holdings PLC
("Sareum"or the "Company")
Notice of Final Results for the for the Year Ended 30 June 2023
and Investor Presentation
Cambridge, UK, 03 October 2023 - Sareum Holdings plc (AIM: SAR),
a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer, will announce its
audited financial results for the year ended 30 June 2023 on
Monday, 9 October 2023.
The Company will also be holding a live presentation to
investors on Wednesday, 11 October 2023 at 10.00 am BST via the
Investor Meet Company ("IMC") platform.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9:00 am BST the day before
the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet SAREUM HOLDINGS PLC via:
https://www.investormeetcompany.com/sareum-holdings-plc/register-investor
Investors who already follow SAREUM HOLDINGS PLC on the Investor
Meet Company platform will automatically be invited.
A copy of the presentation will be made available on the
Company's website following the presentation.
- Ends -
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497700
Lauren Williams, Head of Investor Relations ir@sareum.co.uk
Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman 020 7409 3494
Peel Hunt LLP (Joint Corporate Broker)
James Steel / Patrick Birkholm 020 7418 8900
Hybridan LLP (Joint Corporate Broker)
Claire Noyce
020 3764 2341
ICR Consilium (Financial PR)
Jessica Hodgson / Davide Salvi / Stella
Lempidaki 020 3709 5700
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology
company developing next generation kinase inhibitors for autoimmune
disease and cancer.
The Company is focused on developing next generation small
molecules which modify the activity of the JAK kinase family and
have best-in-class potential. Its lead candidate, SDC-1801,
simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential
treatment for a range of autoimmune diseases and has entered Phase
1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1
inhibitor which it originally developed in collaboration with
several Cancer Research UK-related organisations. SRA737 has shown
promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a
potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on
the AIM market of the London Stock Exchange, trading under the
ticker SAR. For further information, please visit the Company's
website at www.sareum.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCNKBBDFBDDBKK
(END) Dow Jones Newswires
October 03, 2023 02:00 ET (06:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From May 2024 to Jun 2024
Sareum (LSE:SAR)
Historical Stock Chart
From Jun 2023 to Jun 2024